Variants of uncertain significance in BRCA: A harbinger of ethical and policy issues to come?

Genome Medicine

Volumn 6, Issue 12, 2014, Pages

  Cheon, Jae Y ^a   Mozersky, Jessica ^b,c   Cook Deegan, Robert ^a  

^a DUKE UNIVERSITY   (United States)

^b NEW SCHOOL FOR SOCIAL RESEARCH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; HUMAN GENOME; IN VITRO STUDY; MEDICAL ETHICS; MOLECULAR GENETICS; PRIORITY JOURNAL; RISK FACTOR;

EID: 84927741148     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-014-0121-3     Document Type: Article

References (84)

1. Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro ANA, Tavtigian S, Goldgar DE, Couch FJ. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 2012, 33:8-21. 10.1002/humu.21627, 21990134.
2. Eggington JM, Bowles K, Moyes K, Manley S, Esterling L, Sizemore S, Rosenthal E, Theisen A, Saam J, Arnell C. A comprehensive laboratory-based program for classification of variants of uncertain significance in hereditary cancer genes. Clin Genet 2014, 86:229-237. 10.1111/cge.12315, 24304220.
3. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, Chaib H, Merker JD, Goldfeder RL, Enns GM, David SP. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014, 311:1035-1045. 10.1001/jama.2014.1717, 24618965.
4. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS, McGuire V, Ladabaum U, Kobayashi Y, Lincoln SE. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014, 32:2001-2009. 10.1200/JCO.2013.53.6607, 24733792.
5. Futreal PA, Wooster RF, Ashworth A, Stratton MR. Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof. UK Patent GB 2307477 A. Filed 25 November, 1996; issued 29 May, 1997.
6. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71. 10.1126/science.7545954, 7545954.
7. Skolnick MH, Goldgar DE, Miki Y, Swenson J, Kamb A, Harshman KD, Shattuck-Eidens DM, Tavtigian SV, Wiseman RW, Futreal PA. 17Q-linked breast and ovarian cancer susceptibility gene. US patent 5,747,282. Filed 7 June, 1995; issued 5 May, 1998.
8. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792. 10.1038/378789a0, 8524414.
9. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z. SEER Cancer Statistics Review, 1975-2011 2014, National Cancer Institute, Bethesda.
10. Domchek SM, Weber BL. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006, 25:5825-5831. 10.1038/sj.onc.1209881, 16998496.
11. Culver JO, Brinkerhoff CD, Clague J, Yang K, Singh KE, Sand SR, Weitzel JN. Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress. Clin Genet 2013, 84:464-472. 10.1111/cge.12097, 23323793.
12. Clinical Pathology Accreditation & Transfer of Accreditation to UKAS. [http://www.ukas.com/services/CPA/Clinical_Pathology_Accreditation_CPA.asp].
13. Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002, 20:1480-1490. 10.1200/JCO.20.6.1480, 11896095.
14. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FBL, Hoogerbrugge N, Spurdle AB, Tavtigian SV. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008, 29:1282-1291. 10.1002/humu.20880, 18951446.
15. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012, 33:2-7. 10.1002/humu.21628, 21990146.
16. Breast Cancer Information Core: An Open Access On-Line Breast Cancer Mutation Data Base. [http://research.nhgri.nih.gov/bic/].
17. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H. BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. JAMA 1996, 275:1885-1892. 10.1001/jama.1996.03530480027036, 8648868.
18. Tavtigian SV, Greenblatt MS, Goldgar DE, Boffetta P. Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Hum Mutat 2008, 29:1261-1264. 10.1002/humu.20903, 18951436.
19. Association for Molecular Pathology v. Myriad Genetics. Volume 133 2013, Supreme Court of the United States, Washington, DC.
20. Cook-Deegan R, Niehaus A. After Myriad: genetic testing in the wake of recent supreme court decisions about gene patents. Curr Genet Med Rep 2014, 2:223-241. 10.1007/s40142-014-0055-5, 25401053.
21. Ambry Genetics: BRCA and Beyond. [http://brcaandbeyond.com/].
22. Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ. BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. Oncologist 2013, 18:518-524. 10.1634/theoncologist.2012-0452, 23615697.
23. Memorandum Decision and Order Denying Plaintiffs' Motion for Preliminary Injunction 2014, US District Court for Utah, Salt Lake City.
24. Baldwin AL, Cook-Deegan R. Constructing narratives of heroism and villainy: Case study of Myriad's BRACAnalysis® compared to Genentech's Herceptin®. Genome Med 2013, 5:8. 10.1186/gm412, 23369278.
25. Wallis Y, Payne S, McAnulty C, Bodmer D, Sistermans E, Robertson K, Moore D, Abbs S, Deans Z, Devereau A. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics 2013, Association for Clinical Genetic Science, Birmingham.
26. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 2008, 10:294-300. 10.1097/GIM.0b013e31816b5cae, 18414213.
27. Domchek S, Weber BL. Genetic variants of uncertain significance: flies in the ointment. J Clin Oncol 2008, 26:16-17. 10.1200/JCO.2007.14.4154, 18165634.
28. Miller-Samuel S, MacDonald DJ, Weitzel JN, Santiago F, Martino MA, Namey T, Augustyn A, Mueller R, Forman A, Bradbury AR. Variants of uncertain significance in breast cancer-related genes: real-world implications for a clinical conundrum. Part one: clinical genetics recommendations. Semin Oncol 2011, 38:469-480. 10.1053/j.seminoncol.2011.04.008, 21810505.
29. DeMichele A, Weber BL. Risk management in BRCA1 and BRCA2 mutation carriers: lessons learned, challenges posed. J Clin Oncol 2002, 20:1164-1166. 11870156.
30. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996, 85:1009-1023. 10.1016/S0092-8674(00)81302-1, 8674108.
31. Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidelines for interpretation. Ann Oncol 2011, 22:i18-i23. 10.1093/annonc/mdq661, 21285146.
32. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004, 4:850-860. 10.1038/nrc1476, 15516958.
33. Easton Douglas F, Deffenbaugh Amie M, Pruss D, Frye C, Wenstrup Richard J, Allen-Brady K, Tavtigian Sean V, Monteiro Alvaro NA, Iversen Edwin S, Couch Fergus J, Goldgar David E. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007, 81:873-883. 10.1086/521032, 17924331.
34. American College of Medical Genetics and Genomics. ACMG Standards and Guidelines for Clinical Genetics Laboratories 2007, ACMG, Bethesda.
35. Claustres M, Kozich V, Dequeker E, Fowler B, Hehir-Kwa JY, Miller K, Oosterwijk C, Peterlin B, van Ravenswaaij-Arts C, Zimmermann U, Zuffardi O, Hastings RJ, Barton DE. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). Eur J Hum Genet 2014, 22:160-170. 10.1038/ejhg.2013.125, 23942201.
36. Feero W. Clinical application of whole-genome sequencing: proceed with care. JAMA 2014, 311:1017-1019. 10.1001/jama.2014.1718, 24618961.
37. Myriad Genetics: All Products. [http://www.myriad.com/products-services/all-products/overview/].
38. Ambry Genetics: Panels. [http://www.ambrygen.com/panels].
39. Tests offered by GeneDx. [https://www.genedx.com/test-catalog/available-tests/].
40. Invitae Genetics: Test Catalog. [https://www.invitae.com/en/test-catalog/].
41. Quest Diagnostics: Test Center. [http://www.questdiagnostics.com/testcenter/TestCenterHome.action].
42. LabCorp: Integrated Oncology, IntelliGEN. [https://www.labcorp.com/.EdosPortlet/TestMenuLibrary?libName=File+Library&compName=L12684].
43. Counsyl: Family Prep Screen Clinical Information. [https://www.counsyl.com/services/family-prep-screen/clinical-info/].
44. University of Washington, Department of Laboratory Medicine: Genetics and Solid Tumor Diagnostic Testing. [http://depts.washington.edu/labweb/Divisions/MolDiag/MolDiagGen/index.htm].
45. UCLA Clinical Laboratory and Pathology Services: Lung Cancer Mutation Panel. [http://www.crlonline.com/lco/action/doc/retrieve/docid/ucla/4688743].
46. The University of Chicago Genetic Services: Exome Sequencing. [http://dnatesting.uchicago.edu/tests/670].
47. Emory Genetics Laboratory: Molecular Genetic Tests. [http://geneticslab.emory.edu/tests/test-menu.php?filter=2].
48. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. J Clin Oncol 2013, 31:1267-1270. 10.1200/JCO.2012.46.9403, 23460708.
49. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med 2014, 370:2418-2425. 10.1056/NEJMra1312543, 24941179.
50. Yang Y, Muzny DM, Xia F, Niu Z, Person R, Ding Y, Ward P, Braxton A, Wang M, Buhay C, Veeraraghavan N, Hawes A, Chiang T, Leduc M, Beuten J, Zhang J, He W, Scull J, Willis A, Landsverk M, Craigen WJ, Bekheirnia MR, Stray-Pedersen A, Liu P, Wen S, Alcaraz W, Cui H, Walkiewicz M, Reid J, Bainbridge M, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 2014, 312:1870-1879. 10.1001/jama.2014.14601, 25326635.
51. Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009, 27:433-438. 10.1200/JCO.2008.18.5546, 19064968.
52. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006, 296:185-192. 10.1001/jama.296.2.185, 16835424.
53. Caulfield T, Evans J, McGuire A, McCabe C, Bubela T, Cook-Deegan R, Fishman J, Hogarth S, Miller FA, Ravitsky V, Biesecker B, Borry P, Cho MK, Carroll JC, Etchegary H, Joly Y, Kato K, Lee SS, Rothenberg K, Sankar P, Szego MJ, Ossorio P, Pullman D, Rousseau F, Ungar WJ, Wilson B. Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate. PLoS Biol 2013, 11:e1001699. 10.1371/journal.pbio.1001699, 24223516.
54. Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, Braxton A, Beuten J, Xia F, Niu Z, Hardison M, Person R, Bekheirnia MR, Leduc MS, Kirby A, Pham P, Scull J, Wang M, Ding Y, Plon SE, Lupski JR, Beaudet AL, Gibbs RA, Eng CM. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med 2013, 369:1502-1511. 10.1056/NEJMoa1306555, 24088041.
55. Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test 2002, 6:107-113. 10.1089/10906570260199357, 12215249.
56. Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann Oncol 2013, 24:viii69-viii74. 10.1093/annonc/mdt312, 24131974.
57. Plon SE, Cooper HP, Parks B, Dhar SU, Kelly PA, Weinberg AD, Staggs S, Wang T, Hilsenbeck S. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med 2011, 13:148-154. 10.1097/GIM.0b013e318207f564, 21224735.
58. Pyeritz RE. The coming explosion in genetic testing-is there a duty to recontact. N Engl J Med 2011, 365:1367-1369. 10.1056/NEJMp1107564, 21995382.
59. Myriad Presents Clinical Data on Myriad myRisk™ Hereditary Cancer Test at ASCO. [http://globenewswire.com/news-release/2014/06/02/640970/10083950/en/Myriad-Presents-Clinical-Data-on-Myriad-myRisk-TM-Hereditary-Cancer-Test-at-ASCO.html].
60. Myriad Genetics Announces Participation In Innovative Collaboration to Accelerate Hereditary Cancer Research. [http://investor.myriad.com/releasedetail.cfm?releaseid=851822].
61. Allyse M, Sayres L, Havard M, King J, Greely H, Hudgins L, Taylor J, Norton M, Cho M, Magnus D. Best ethical practices for clinicians and laboratories in the provision of noninvasive prenatal testing. Prenat Diagn 2013, 33:656-661. 10.1002/pd.4144, 23613322.
62. Angrist M, Jamal L. Living laboratory: whole-genome sequencing as a learning healthcare enterprise. Clin Genet. 2014. doi:10.1111/cge.12461.
63. Wilfond BS, Nolan K. National policy development for the clinical application of genetic diagnostic technologies: lessons from cystic fibrosis. JAMA 1993, 270:2948-2954. 10.1001/jama.1993.03510240060033, 8254856.
64. Stanley CM, Sunyaev SR, Greenblatt MS, Oetting WS. Clinically relevant variants-identifying, collecting, interpreting, and disseminating: the 2013 annual scientific meeting of the human genome variation society. Hum Mutat 2014, 35:505-510. 10.1002/humu.22516, 24470180.
65. What is ClinVar?. [http://www.ncbi.nlm.nih.gov/clinvar/intro/].
66. The Global Alliance for Genomics & Health. [http://genomicsandhealth.org/].
67. Sharing Clinical Reports Project (SCRP). [http://sharingclinicalreports.org/].
68. Free the Data. [http://www.free-the-data.org/].
69. Multiple Institutions, Labs Collaborating on Registry to Study Rare Hereditary Cancer Genes. [https://www.genomeweb.com/clinical-genomics/multiple-institutions-labs-collaborating-registry-study-rare-hereditary-cancer-g].
70. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond KE. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013, 15:565-574. 10.1038/gim.2013.73, 23788249.
71. Parthasarathy S. Building Genetic Medicine: Breast Cancer, Technology, and the Comparative Politics of Health Care 2012, MIT Press, Cambridge.
72. Gold ER, Carbone J. Myriad Genetics: In the eye of the policy storm. Genet Med 2010, 12:S39-S70. 10.1097/GIM.0b013e3181d72661, 20393310.
73. How a Gene-Patent Test Case Will Help Both Patients and Inventors. [http://www.theglobeandmail.com/globe-debate/how-a-gene-patent-test-case-will-help-both-patients-and-inventors/article21437174/].
74. Van Zimmeren E, Nicol D, Gold R, Carbone J, Chandrasekharan S, Baldwin AL, Cook-Deegan R: The BRCA patent controversies. In Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA. Edited by Gibbon S, Joseph G, Mozersky J, Nieden AZ, Palfner S. New York: Routledge; 2014:151-174.
75. Nicol D, Nielsen JL, Liddicoat JE, Critchley C, Whitton T. The special case of genetic testing. The Innovation Pool in Biotechnology: The Role of Patents in Facilitating Innovation 2014, 149. Social Science Research Network, Rochester.
76. ISO 15189:2012 Medical Laboratories -- Requirements for Quality and Competence. [http://www.iso.org/iso/catalogue_detail?csnumber=56115].
77. Accreditation and Laboratory Improvement. College of American Pathologists 2014 [http://www.cap.org/apps/cap.portal?_nfpb=true&_pageLabel=accreditation].
78. DesRoches CM, Charles D, Furukawa MF, Joshi MS, Kralovec P, Mostashari F, Worzala C, Jha AK. Adoption of electronic health records grows rapidly, but fewer than half of US hospitals had at least a basic system in 2012. Health Aff 2013, 32:1478-1485. 10.1377/hlthaff.2013.0308.
79. Jha AK, DesRoches CM, Campbell EG, Donelan K, Rao SR, Ferris TG, Shields A, Rosenbaum S, Blumenthal D. Use of electronic health records in U.S. hospitals. N Engl J Med 2009, 360:1628-1638. 10.1056/NEJMsa0900592, 19321858.
80. Jha AK, DesRoches CM, Kralovec PD, Joshi MS. A progress report on electronic health records in U.S. hospitals. Health Aff 2010, 29:1951-1957. 10.1377/hlthaff.2010.0502.
81. PCORnet: The National Patient-Centered Clinical Research Network. [http://www.pcori.org/funding-opportunities/pcornet-national-patient-centered-clinical-research-network/].
82. Genetic Alliance. [http://www.geneticalliance.org/about].
83. Facing Our Risk of Cancer Empowered. [http://www.facingourrisk.org/index.php].
84. Duchenne Connect. [https://www.duchenneconnect.org/].